skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

What is clinical and research excellence?

The pharmaceutical industry develops drugs and interventions that benefit society, allowing us to live healthier, happier, more productive, and more fulfilling lives. Between 2000 and 2009, medicines contributed 73% of the 21-month life expectancy increase. Medicines have also led to 83% of survival gains in cancer, and prevented 862,000 deaths since the mid-90s in the United States alone.

However, these new medicines don’t come without a struggle, and pharma R&D remains one of the highest risk business areas. In fact, 85% of medicines in development fail to reach approval while 30% of marketed drugs don’t make enough money to cover their R&D costs.

Clinical and research excellence has numerous interpretations and definitions, ranging from the unwavering commitment to identify a cure for the rarest, unmet needs to demonstrated innovation or R&D effectiveness. At Pharma Intelligence, we both celebrate and support the dialogue.

 

The CARE Index


Based on a series of key R&D indicators that leverage our proprietary R&D data sets, Pharma Intelligence developed a definitive index of clinical and research excellence. The CARE Index also allows you to create your own version by adjusting indicator weightings to reflect what clinical and research excellence means to you, and compare this with ones created by our analysts and journalists.

 

The CARE Awards


The CARE Awards are dedicated to recognizing clinical achievements in the pharmaceutical industry. The awards showcase excellence in clinical trial design, technological advancements and results, as well as the outstanding achievements of individuals, departments, teams or organizations. Winners will have contributed to the advancement of therapies for unmet medical needs, undertaken ground-breaking collaborations, and contributed to positive clinical outcomes, with a focus on best practice and innovation.


The CARE Awards 2018
took place April 25 at the Boston Harbor Hotel to celebrate the wealth of innovation, unwavering commitment and passion to make human lives better.

The CARE Awards 2017 was held in Boston in the State Room on Wednesday, April 5, 2017.

無料の最新記事&レポート

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    Q4 2019 Outlook Report Extract

    16 Oct 2019

    What major drug catalysts and events can you expect to see this quarter? Get a view of what's to come with an extract from the full report.

    Topic clinical-trials drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Q3 2019 Catalyst Roundup

    16 Oct 2019

    What were the outcomes of critical catalysts featured in Biomedtracker’s Q3 2019 Outlook Report? Find out in the Catalyst Roundup: A Review of Select Catalysts from Last Quarter’s Outlook Report. This data-rich graphic is available now – for free.

    Topic Drug approval Drug review FDA

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    Key potential drug launches 2020

    27 Sep 2019

    Take a longer-term look at key late-stage drugs projected to hit the market in 2020, including new drug classes, major changes to standards of care, and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.

    Topic drug-approval drug-review drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker: Improved Custom Company Portfolio Feature

    04 Sep 2019

    Discover how creating custom company portfolios can help you overcome your toughest business challenges. 

    Topic business-strategies

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Q3 2019 Outlook Report Extract

    29 Jul 2019

    In this report, we cover catalysts from 27 drugs, devices and diagnostics expected to occur in Q3 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.   

    Topic Drug development landscape Drug review Research Strategy

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    2019 Q3 Outlook Webinar

    15 Jul 2019

    Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

    Topic immuno-oncology Infectious diseases

  • Meddevicetracker: 医療機器の市場調査分析・データベース, Biomedtracker: 開発中医薬品を...

    When Part of the Picture Isn't Enough

    05 Jul 2019

    Staying on top of what’s going in the competitive Medtech market and getting a complete view of the competitive landscape and current market trends is critical to your business. Often, this essential information is fragmented and difficult to find, and gathering and synthesizing it is tedious and time consuming. Now, Biomedtracker puts this critical information at your fingertips, saving you time and effort. The new “Associated Products” section on relevant Biomedtracker Drug Profile pages shows you the full competitive landscape – including drugs, devices, and diagnostics – with a single search.

    Topic business-strategies medtech

  • Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...

    Q1 Outlook Webinar: Key Catalysts and their Impact on Pharma Markets

    By Michael ​ Haydock 02 Jul 2019

    Find out which market-moving events and catalysts to watch for during the Q1 Outlook Webinar - Key catalysts and their impact on pharma markets.

    Topic drug-approval drug-development-landscape drug-review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker: Catalyst Roundup 2018 Q4

    02 Jul 2019

    A Review of Select Catalysts from Last Quarter’s Outlook Report.

    Topic clinical-trials drug-approval drug-review drug-development-landscape

  • Meddevicetracker: 医療機器の市場調査分析・データベース, Biomedtracker: 開発中医薬品を...

    Q2 2019 Outlook Report

    03 May 2019

    In this report, we cover catalysts from 25 drugs, devices and diagnostics expected to occur in Q2 2019. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    Topic drug-approval drug-development-landscape drug-review

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Datamonitor Healthcare: 医療...

    December 2018 National Influenza Week

    10 Apr 2019

    3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:

    Topic influenza-virus infectious-diseases

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker 2018 Early Outlook Report

    10 Apr 2019

    What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topic drug-development-landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価, Meddevicetracker: 医療機器の市場調...

    Biomedtracker: Early 2019 Outlook Report Extract

    10 Apr 2019

    In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in early 2019.

    Topic drug-approval drug-review medtech

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets

    19 Nov 2018

    Understand important upcoming milestones that will impact the likelihood of drug approval or future sales potential for key therapies during a free webinar from Informa Pharma Intelligence, "Q4 Outlook Webinar - Key Catalysts and their Impact on Pharma Markets".

    Topic Drug development landscape

  • Biomedtracker: 開発中医薬品をFDA承認確率で評価

    Biomedtracker Q4 2018 Outlook Report

    19 Oct 2018

    Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.

    Topic drug-development-landscape